A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells

  title={A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells},
  author={Natalya M Kogan and Cristina Blázquez and Luis Álvarez and Ruth Gallily and Michael Schlesinger and Manuel Guzm{\'a}n and Raphael Mechoulam},
  journal={Molecular Pharmacology},
  pages={51 - 59}
Recent findings on the inhibition of angiogenesis and vascular endothelial cell proliferation by anthracycline antibiotics, which contain a quinone moiety, make this type of compound a very promising lead in cancer research/therapy. We have reported that a new cannabinoid anticancer quinone, cannabidiol hydroxyquinone (HU-331), is highly effective against tumor xenografts in nude mice. For evaluation of the antiangiogenic action of cannabinoid quinones, collagen-embedded rat aortic ring assay… 

Figures and Tables from this paper

HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

The cannabinoid quinone HU-331 is a highly specific inhibitor of topoisomerase II, compared with most known anticancer quinones, and might represent a new potent anticancer drug.

Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.

Results demonstrate that CB1 signaling participates to the proliferative response elicited by proangiogenic growth factors in angiogenesis and that for this reason CB1 receptor could represent a novel target for the treatment of diseases where excessive neoangiogenesis is the underlying pathology.

Cannabinoids as Potential Antitumoral Agents in Pancreatic Cancer

The fair safety profile of THC, together with its possible growth-inhibiting action on tumor cells, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids in other types of tumors such as pancreatic adenocarcinomas.

Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2.

It is demonstrated that cannabinoid WIN-55,212-2 may significantly potentiate the antiproliferative, antimetastasis and antiangiogenic effects of ADM against MG-63 cells via the downregulation of Notch-1, MMP-2 and VEGF.

Cannabinoids and Gliomas

The good safety profile of THC, together with its possible growth-inhibiting action on tumor cells, justifies the setting up of future trials aimed at evaluating the potential antitumoral activity of cannabinoids.

Cannabidiol oxidation product HU-331 is a potential anticancer cannabinoid-quinone: a narrative review

A brief review of the literature related to the activity of HU-331 in purified systems, cancer cell lines, and animal models supports further exploration of H U-331 for the treatment of cancer and possibly other disease states.

Fibrinogen‐derived fibrinostatin inhibits tumor growth through anti‐angiogenesis

It is demonstrated that fibrinostatin has anti‐angiogenesis activity in several angiogenesis models and it reduces tumor growth in mouse xenografts and allografted models and has a wide margin of safety.

Cannabinoids as anticancer drugs: current status of preclinical research

This review provides an up-to-date overview of the potential of cannabinoids as inhibitors of tumour growth and spread as demonstrated in preclinical studies.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer

It is observed that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/prostaglandin E2 signaling pathways and induction of apoptosis.



Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas

Cannabinoids inhibit tumor angiogenesis in mice, but the mechanism of their antiangiogenic action is still unknown. Because the vascular endothelial growth factor (VEGF) pathway plays a critical role

Inhibition of tumor angiogenesis by cannabinoids

It is shown that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays.

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.

It is shown that the CB(1) and theCB(2) receptor are expressed in normal skin and skin tumors of mice and humans and support a new therapeutic approach for the treatment of skin tumors.

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

The data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous Prolactin action at the level of prolactin receptor.

Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis

The findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.

Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor

It is demonstrated that anandamide, Δ9-tetrahydrocannabinol (THC), HU-210, and Win55,212-2 promote mitogenic kinase signaling in cancer cells and thereby contribute to cancer progression in patients.

Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes

The inhibitory effect of the endogenous substance anandamide on both tumor cell and lymphocyte migration is reported, suggesting specific inhibition of tumor cell migration via CB1-R engagement might be a selective tool to prevent metastasis formation without depreciatory effects on the immune system of cancer patients.

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

A dual mechanism of action is proposed: indirect tumor cell kill via the destruction of tumor endothelium by NGR-targeted liposomes and direct tumorcell kill via localization of liposomal DXR to the tumor interstitial space and has the potential to overcome some major limitations of conventional chemotherapy.

Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.

It is shown that PEA potently enhances the anti-proliferative effects of AEA on human breast cancer cells (HBCCs), in part by inhibiting the expression of fatty acid amide hydrolase (FAAH), the major enzyme catalysing AEA degradation.

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

The findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential negative effectors of PRL- and NGF-induced biological responses, at least in some cancer cells.